Target Name: VWC2L
NCBI ID: G402117
Other Name(s): VWC2-like protein | Von Willebrand factor C domain-containing protein 2-like | VWC2L_HUMAN | Von Willebrand factor C domain-containing protein 2-like (isoform 1) | Von Willebrand factor C domain containing 2 like, transcript variant 1 | Brorin-like | von Willebrand factor C domain containing protein 2 like | VWC2L variant 1 | von Willebrand factor C domain containing 2 like | von Willebrand factor C domain-containing protein 2-like | brorin-like

VWC2L: A Potential Drug Target and Biomarker

Vascular volume and growth-controlled protein 2 (VWC2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. VWC2 is a member of the voltage-activated ion channels (VAC) family, which are involved in the regulation of ion traffic and neurotransmitter release. The VAC family has been implicated in a wide range of physiological processes, including neuronal excitability and survival, and VWC2 has been shown to play a role in several physiological processes, including blood pressure, inflammation, and neurodegeneration.

Recent studies have suggested that VWC2 may be a promising drug target for several diseases. For example, VWC2 has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, VWC2 has been shown to be involved in the regulation of neurotransmitter release and has been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

One potential mechanism by which VWC2 may be involved in the development of cancer is by regulating the angiogenesis (the formation of new blood vessels) that allows cancer cells to receive the necessary oxygen and nutrients for growth and survival. Several studies have shown that VWC2 plays a role in the regulation of angiogenesis and that alterations in VWC2 activity may contribute to the development of cancer. For example, one study found that inhibiting VWC2 activity with a small molecule inhibitor improved the growth and survival of cancer cells, suggesting that VWC2 may be a potential drug target for cancer.

Another potential mechanism by which VWC2 may be involved in the development of neurodegenerative diseases is by regulating the production and degradation of neurotransmitters, which are important for the function and survival of nerve cells. Several studies have shown that VWC2 is involved in the regulation of neurotransmitter release and that alterations in VWC2 activity may contribute to the development and progression of neurodegenerative diseases. For example, one study found that VWC2 was involved in the regulation of dopamine release and that alterations in VWC2 activity may contribute to the development of neurodegenerative diseases, such as Parkinson's disease.

In addition to its potential role in the regulation of neurotransmitter release, VWC2 has also been shown to play a role in the regulation of blood pressure and inflammation. Several studies have shown that VWC2 is involved in the regulation of blood pressure and that alterations in VWC2 activity may contribute to the development and progression of cardiovascular diseases. For example, one study found that VWC2 was involved in the regulation of nitric oxide production and that alterations in VWC2 activity may contribute to the development of cardiovascular disease.

Given the potential role of VWC2 in several physiological processes, it is a promising target for drug development. Several small molecules have been shown to be involved in the regulation of VWC2 activity, and further studies are needed to determine the most effective and safe compounds to use as drug candidates. Further research is also needed to understand the full role of VWC2 in the regulation of physiological processes and its potential as a drug target.

In conclusion, VWC2 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The VAC family of proteins, of which VWC2 is a member, is involved in the regulation of several physiological processes, including blood pressure, inflammation, and neurotransmission. Further studies are needed to determine the role of VWC2 in the regulation of physiological processes and its potential as a drug target.

Protein Name: Von Willebrand Factor C Domain Containing 2 Like

Functions: May play a role in neurogenesis. May play a role in bone differentiation and matrix mineralization

More Common Targets

VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82